The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study
Sodium−glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2 diabetes (T2D). As platelet activation and oxidative stress play a key role in atherothrombotic-related complications, we hypothesized that gliflozi...
Saved in:
| Published in | Antioxidants Vol. 11; no. 10; p. 1878 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
22.09.2022
MDPI |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Sodium−glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2 diabetes (T2D). As platelet activation and oxidative stress play a key role in atherothrombotic-related complications, we hypothesized that gliflozins might modulate oxidative stress, platelet activation and thrombus formation. We performed an interventional open-label single-arm before-after study in 32 T2D patients on top of their ongoing metformin therapy. The population was divided into two groups: treatment with GLP-1 receptor agonists (GLP-1RA, Group A) and gliflozins (Group B). Oxidative stress, platelet activation and thrombus growth were assessed before and after 15 days of treatment. Compared to the baseline, gliflozins treatment significantly decreased sNOX2-dp (−45.2%, p < 0.001), H2O2 production (−53.4%, p < 0.001), TxB2 (−33.1%, p < 0.001), sP-selectin (−49.3%, p < 0.001) and sCD40L levels (−62.3%, p < 0.001) as well as thrombus formation (−32%, p < 0.001), whereas it potentiated anti-oxidant power (HBA, +30.8%, p < 0.001). Moreover, a significant difference in oxidative stress, platelet activation and thrombus formation across groups A and B was found. In addition, an in vitro study on stimulated platelets treated with gliflozins (10−30 μM) showed a reduction in oxidative stress, platelet activation and thrombus growth. Our results showed that gliflozins have antiplatelet and antithrombic activity related to an NOX2 down-regulation, suggesting a new mechanism responsible for cardiovascular protection. |
|---|---|
| AbstractList | Sodium-glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2 diabetes (T2D). As platelet activation and oxidative stress play a key role in atherothrombotic-related complications, we hypothesized that gliflozins might modulate oxidative stress, platelet activation and thrombus formation. We performed an interventional open-label single-arm before-after study in 32 T2D patients on top of their ongoing metformin therapy. The population was divided into two groups: treatment with GLP-1 receptor agonists (GLP-1RA, Group A) and gliflozins (Group B). Oxidative stress, platelet activation and thrombus growth were assessed before and after 15 days of treatment. Compared to the baseline, gliflozins treatment significantly decreased sNOX2-dp (−45.2%, p < 0.001), H[sub.2] O[sub.2] production (−53.4%, p < 0.001), TxB2 (−33.1%, p < 0.001), sP-selectin (−49.3%, p < 0.001) and sCD40L levels (−62.3%, p < 0.001) as well as thrombus formation (−32%, p < 0.001), whereas it potentiated anti-oxidant power (HBA, +30.8%, p < 0.001). Moreover, a significant difference in oxidative stress, platelet activation and thrombus formation across groups A and B was found. In addition, an in vitro study on stimulated platelets treated with gliflozins (10-30 μM) showed a reduction in oxidative stress, platelet activation and thrombus growth. Our results showed that gliflozins have antiplatelet and antithrombic activity related to an NOX2 down-regulation, suggesting a new mechanism responsible for cardiovascular protection. Sodium–glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2 diabetes (T2D). As platelet activation and oxidative stress play a key role in atherothrombotic-related complications, we hypothesized that gliflozins might modulate oxidative stress, platelet activation and thrombus formation. We performed an interventional open-label single-arm before-after study in 32 T2D patients on top of their ongoing metformin therapy. The population was divided into two groups: treatment with GLP-1 receptor agonists (GLP-1RA, Group A) and gliflozins (Group B). Oxidative stress, platelet activation and thrombus growth were assessed before and after 15 days of treatment. Compared to the baseline, gliflozins treatment significantly decreased sNOX2-dp (−45.2%, p < 0.001), H2O2 production (−53.4%, p < 0.001), TxB2 (−33.1%, p < 0.001), sP-selectin (−49.3%, p < 0.001) and sCD40L levels (−62.3%, p < 0.001) as well as thrombus formation (−32%, p < 0.001), whereas it potentiated anti-oxidant power (HBA, +30.8%, p < 0.001). Moreover, a significant difference in oxidative stress, platelet activation and thrombus formation across groups A and B was found. In addition, an in vitro study on stimulated platelets treated with gliflozins (10–30 μM) showed a reduction in oxidative stress, platelet activation and thrombus growth. Our results showed that gliflozins have antiplatelet and antithrombic activity related to an NOX2 down-regulation, suggesting a new mechanism responsible for cardiovascular protection. Sodium–glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2 diabetes (T2D). As platelet activation and oxidative stress play a key role in atherothrombotic-related complications, we hypothesized that gliflozins might modulate oxidative stress, platelet activation and thrombus formation. We performed an interventional open-label single-arm before-after study in 32 T2D patients on top of their ongoing metformin therapy. The population was divided into two groups: treatment with GLP-1 receptor agonists (GLP-1RA, Group A) and gliflozins (Group B). Oxidative stress, platelet activation and thrombus growth were assessed before and after 15 days of treatment. Compared to the baseline, gliflozins treatment significantly decreased sNOX2-dp (−45.2%, p < 0.001), H 2 O 2 production (−53.4%, p < 0.001), TxB2 (−33.1%, p < 0.001), sP-selectin (−49.3%, p < 0.001) and sCD40L levels (−62.3%, p < 0.001) as well as thrombus formation (−32%, p < 0.001), whereas it potentiated anti-oxidant power (HBA, +30.8%, p < 0.001). Moreover, a significant difference in oxidative stress, platelet activation and thrombus formation across groups A and B was found. In addition, an in vitro study on stimulated platelets treated with gliflozins (10–30 μM) showed a reduction in oxidative stress, platelet activation and thrombus growth. Our results showed that gliflozins have antiplatelet and antithrombic activity related to an NOX2 down-regulation, suggesting a new mechanism responsible for cardiovascular protection. Sodium−glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2 diabetes (T2D). As platelet activation and oxidative stress play a key role in atherothrombotic-related complications, we hypothesized that gliflozins might modulate oxidative stress, platelet activation and thrombus formation. We performed an interventional open-label single-arm before-after study in 32 T2D patients on top of their ongoing metformin therapy. The population was divided into two groups: treatment with GLP-1 receptor agonists (GLP-1RA, Group A) and gliflozins (Group B). Oxidative stress, platelet activation and thrombus growth were assessed before and after 15 days of treatment. Compared to the baseline, gliflozins treatment significantly decreased sNOX2-dp (−45.2%, p < 0.001), H2O2 production (−53.4%, p < 0.001), TxB2 (−33.1%, p < 0.001), sP-selectin (−49.3%, p < 0.001) and sCD40L levels (−62.3%, p < 0.001) as well as thrombus formation (−32%, p < 0.001), whereas it potentiated anti-oxidant power (HBA, +30.8%, p < 0.001). Moreover, a significant difference in oxidative stress, platelet activation and thrombus formation across groups A and B was found. In addition, an in vitro study on stimulated platelets treated with gliflozins (10−30 μM) showed a reduction in oxidative stress, platelet activation and thrombus growth. Our results showed that gliflozins have antiplatelet and antithrombic activity related to an NOX2 down-regulation, suggesting a new mechanism responsible for cardiovascular protection. |
| Audience | Academic |
| Author | Buzzetti, Raffaella Del Ben, Maria Siena, Antonio Maddaloni, Ernesto Violi, Francesco Cocomello, Nicholas Pignatelli, Pasquale Baratta, Francesco Cammisotto, Vittoria Pingitore, Annachiara Chiariello, Giovanni Alfonso Pastori, Daniele Carnevale, Roberto Castellani, Valentina Santilli, Francesca Bartimoccia, Simona D'Amico, Alessandra D'Onofrio, Luca |
| AuthorAffiliation | 3 Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy 2 Mediterranea Cardiocentro, 80122 Napoli, Italy 7 Department of Medicine and Aging, Center for Advanced Studies and Technology (CAST), “G. d’Annunzio” University Foundation, 66100 Chieti, Italy 6 Cardiovascular Sciences Department, Agostino Gemelli Foundation Polyclinic IRCCS, Catholic University of the Sacred Heart, 00168 Rome, Italy 4 Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, 00135 Rome, Italy 5 Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, 00161 Rome, Italy 8 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 40100 Latina, Italy 1 Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy |
| AuthorAffiliation_xml | – name: 5 Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, 00161 Rome, Italy – name: 2 Mediterranea Cardiocentro, 80122 Napoli, Italy – name: 3 Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy – name: 6 Cardiovascular Sciences Department, Agostino Gemelli Foundation Polyclinic IRCCS, Catholic University of the Sacred Heart, 00168 Rome, Italy – name: 1 Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy – name: 7 Department of Medicine and Aging, Center for Advanced Studies and Technology (CAST), “G. d’Annunzio” University Foundation, 66100 Chieti, Italy – name: 4 Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, 00135 Rome, Italy – name: 8 Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 40100 Latina, Italy |
| Author_xml | – sequence: 1 givenname: Pasquale orcidid: 0000-0002-2265-7455 surname: Pignatelli fullname: Pignatelli, Pasquale organization: Mediterranea Cardiocentro, 80122 Napoli, Italy – sequence: 2 givenname: Francesco orcidid: 0000-0003-1708-272X surname: Baratta fullname: Baratta, Francesco organization: Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy – sequence: 3 givenname: Raffaella surname: Buzzetti fullname: Buzzetti, Raffaella organization: Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy – sequence: 4 givenname: Alessandra orcidid: 0000-0002-5571-4583 surname: D'Amico fullname: D'Amico, Alessandra organization: Department of Movement, Human and Health Sciences, University of Rome "Foro Italico", 00135 Rome, Italy – sequence: 5 givenname: Valentina surname: Castellani fullname: Castellani, Valentina organization: Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, 00161 Rome, Italy – sequence: 6 givenname: Simona surname: Bartimoccia fullname: Bartimoccia, Simona organization: Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy – sequence: 7 givenname: Antonio surname: Siena fullname: Siena, Antonio organization: Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy – sequence: 8 givenname: Luca orcidid: 0000-0003-3905-0139 surname: D'Onofrio fullname: D'Onofrio, Luca organization: Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy – sequence: 9 givenname: Ernesto surname: Maddaloni fullname: Maddaloni, Ernesto organization: Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy – sequence: 10 givenname: Annachiara surname: Pingitore fullname: Pingitore, Annachiara organization: Department of General Surgery and Surgical Specialty Paride Stefanini, Sapienza University of Rome, 00161 Rome, Italy – sequence: 11 givenname: Giovanni Alfonso surname: Chiariello fullname: Chiariello, Giovanni Alfonso organization: Cardiovascular Sciences Department, Agostino Gemelli Foundation Polyclinic IRCCS, Catholic University of the Sacred Heart, 00168 Rome, Italy – sequence: 12 givenname: Francesca orcidid: 0000-0002-4593-905X surname: Santilli fullname: Santilli, Francesca organization: Department of Medicine and Aging, Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University Foundation, 66100 Chieti, Italy – sequence: 13 givenname: Daniele orcidid: 0000-0001-6357-5213 surname: Pastori fullname: Pastori, Daniele organization: Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy – sequence: 14 givenname: Nicholas orcidid: 0000-0002-4922-4318 surname: Cocomello fullname: Cocomello, Nicholas organization: Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy – sequence: 15 givenname: Francesco surname: Violi fullname: Violi, Francesco organization: Mediterranea Cardiocentro, 80122 Napoli, Italy – sequence: 16 givenname: Maria orcidid: 0000-0003-1199-8454 surname: Del Ben fullname: Del Ben, Maria organization: Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy – sequence: 17 givenname: Vittoria orcidid: 0000-0003-1966-5945 surname: Cammisotto fullname: Cammisotto, Vittoria organization: Department of Clinical, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy – sequence: 18 givenname: Roberto orcidid: 0000-0002-6216-9595 surname: Carnevale fullname: Carnevale, Roberto organization: Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 40100 Latina, Italy |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36290601$$D View this record in MEDLINE/PubMed |
| BookMark | eNptklFv0zAQxyM0xMbYK4_IEi_jIcN2HCfmAamqWKlU0WkrEm-W41xaV4ld7KRsH4dvikvH1KLZD7bvfve_O-teJyfWWUiStwRfZZnAH5XtjbsnhGBSFuWL5IzigqeZoOTk4H6aXISwxnEJkpVYvEpOM04F5picJb8XK0B3rjZDl07aQbsAaOzShVc2bJzvwacUXd5NZgv6AU3tylSmdz6gW6gHDeimVT200KOR7s1WxXIsUrZGi5V3XTUEdO18tzdXD2jmfoE3dom-zX_Q9BZ2wTWa35s6IttYR-8hhE9ohG5M6_r4HuqHN8nLRrUBLh7P8-T79ZfF-Gs6m0-m49Es1XlO-pTmImdEaS5EXuU1YOAUlGg4J9FFMiC0LCqsolMxnkNRMZJpDpnioiirJjtPpnvd2qm13HjTKf8gnTLyr8H5pVS-N7oFWfCaacIa3FSUcR0z0prnglU6L0UJLGp93mtthqqDWoPtvWqPRI891qzk0m2lyEXJip3A5aOAdz8HCL3sTNDQtsqCG4KkBY1Jc5zTiL7_D127wdv4VTuqZBRjckAtVWzA2MbFvHonKkcFY5SyjIhIXT1DxV1DZ3QcvsZE-3MB2rsQPDRPPRIsdzMqj2c0Brw7_Jkn_N9EZn8AqDXjBw |
| CitedBy_id | crossref_primary_10_3390_antiox13010016 crossref_primary_10_3390_ijerph20176671 crossref_primary_10_1016_j_jep_2024_118337 crossref_primary_10_3390_antiox12020429 crossref_primary_10_3390_jcm13051508 crossref_primary_10_1080_07853890_2024_2304667 crossref_primary_10_1093_cvr_cvae047 crossref_primary_10_3390_ijms24097789 crossref_primary_10_3389_fcvm_2024_1339094 |
| Cites_doi | 10.1016/j.freeradbiomed.2020.03.033 10.1186/s12933-021-01264-z 10.1111/dom.12054 10.1172/JCI92450 10.1161/01.ATV.0000145574.90840.7d 10.1056/NEJMoa1504347 10.1161/JAHA.114.000920 10.1056/NEJMoa1911303 10.1056/NEJMoa1611925 10.1186/s12933-019-0952-8 10.2337/db11-1243 10.1016/j.diabres.2014.02.014 10.1007/s00125-021-05498-0 10.1161/ATVBAHA.110.206425 10.1016/j.dsx.2021.102382 10.1016/j.bcp.2020.114276 10.1056/NEJMoa1812389 10.1038/194927b0 10.2337/dc12-2469 10.1111/bcp.13589 10.1056/NEJMoa2022190 10.1016/j.ancard.2017.10.011 10.1016/j.tcm.2014.03.003 10.1055/s-0039-1693411 10.2337/dc09-2013 10.1016/S2213-8587(13)70084-6 10.1055/s-0031-1285833 10.1016/j.jcin.2011.03.001 10.1016/S2213-8587(13)70050-0 10.1161/CIRCULATIONAHA.120.047965 10.1016/S0140-6736(10)60407-2 10.1161/ATVBAHA.109.198622 10.1002/dmrr.3047 10.1186/s12933-020-01016-5 10.1155/2018/1232583 10.1056/NEJMoa1504720 10.2337/dc15-S005 10.2337/db15-1141 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2022 MDPI AG 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022 by the authors. 2022 |
| Copyright_xml | – notice: COPYRIGHT 2022 MDPI AG – notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022 by the authors. 2022 |
| DBID | NPM AAYXX CITATION 7QR 7T5 7TO 8FD 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 GNUQQ H94 HCIFZ LK8 M7P P64 PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.3390/antiox11101878 |
| DatabaseName | PubMed CrossRef Chemoreception Abstracts Immunology Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Engineering Research Database ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Biological Science Collection Biological Science Database Biotechnology and BioEngineering Abstracts Publicly Available Content (ProQuest) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Student Oncogenes and Growth Factors Abstracts Technology Research Database ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection Biotechnology and BioEngineering Abstracts ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 2076-3921 |
| ExternalDocumentID | oai_doaj_org_article_76d4c14f0fb246c9952d6594bc5898e4 A744224319 10_3390_antiox11101878 36290601 |
| Genre | Journal Article |
| GeographicLocations | United States St Louis Missouri United States--US |
| GeographicLocations_xml | – name: United States – name: St Louis Missouri – name: United States--US |
| GrantInformation_xml | – fundername: Ateneo Sapienza 2021 of Vittoria Cammisotto grantid: AR22117A883B9B1E |
| GroupedDBID | 53G 5VS 8FE 8FH AADQD AAFWJ AAHBH ADBBV AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS BBNVY BCNDV BENPR BHPHI CCPQU GROUPED_DOAJ HCIFZ HYE IAO ITC KQ8 LK8 M48 M7P MODMG M~E NPM OK1 PGMZT PIMPY PROAC RPM AAYXX CITATION 7QR 7T5 7TO 8FD ABUWG AZQEC DWQXO FR3 GNUQQ H94 P64 PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c551t-259541ac6995b5de0e62ea9f66125913e1287b0a5b5a465e7b413c6e3a6978bf3 |
| IEDL.DBID | RPM |
| ISSN | 2076-3921 |
| IngestDate | Tue Oct 22 15:12:55 EDT 2024 Tue Sep 17 21:30:53 EDT 2024 Fri Oct 25 22:01:47 EDT 2024 Thu Oct 10 17:24:23 EDT 2024 Tue Nov 19 21:11:04 EST 2024 Tue Nov 12 23:30:52 EST 2024 Fri Dec 06 08:49:10 EST 2024 Sat Sep 28 08:18:51 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | thrombosis type 2 diabetes gliflozins oxidative stress platelet activation |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c551t-259541ac6995b5de0e62ea9f66125913e1287b0a5b5a465e7b413c6e3a6978bf3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. |
| ORCID | 0000-0002-6216-9595 0000-0002-5571-4583 0000-0003-1199-8454 0000-0003-1708-272X 0000-0001-6357-5213 0000-0002-4922-4318 0000-0003-1966-5945 0000-0003-3905-0139 0000-0002-4593-905X 0000-0002-2265-7455 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598474/ |
| PMID | 36290601 |
| PQID | 2728420012 |
| PQPubID | 2032435 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_76d4c14f0fb246c9952d6594bc5898e4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9598474 proquest_miscellaneous_2729525052 proquest_journals_2728420012 gale_infotracmisc_A744224319 gale_infotracacademiconefile_A744224319 crossref_primary_10_3390_antiox11101878 pubmed_primary_36290601 |
| PublicationCentury | 2000 |
| PublicationDate | 20220922 |
| PublicationDateYYYYMMDD | 2022-09-22 |
| PublicationDate_xml | – month: 9 year: 2022 text: 20220922 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Antioxidants |
| PublicationTitleAlternate | Antioxidants (Basel) |
| PublicationYear | 2022 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | McMurray (ref_34) 2019; 381 Carnevale (ref_7) 2014; 3 Born (ref_27) 1962; 194 Krotz (ref_33) 2004; 24 (ref_25) 2015; 38 Nocella (ref_29) 2020; 152 Matsushima (ref_8) 2014; 24 Zinman (ref_21) 2015; 373 Lee (ref_11) 2022; 16 Oeseburg (ref_14) 2010; 30 Lescano (ref_23) 2020; 182 Batzias (ref_36) 2018; 2018 Avila (ref_38) 2012; 120 Hasan (ref_15) 2014; 104 Sposito (ref_37) 2021; 20 Angiolillo (ref_9) 2011; 4 Dave (ref_10) 2021; 143 Ceriello (ref_13) 2013; 36 Kohlmorgen (ref_31) 2021; 64 Reheman (ref_12) 2016; 65 Spigoni (ref_32) 2020; 19 Picard (ref_5) 2017; 66 Stenlof (ref_19) 2013; 15 Tancredi (ref_2) 2015; 373 Roden (ref_18) 2013; 1 Carnevale (ref_28) 2018; 84 Kraakman (ref_24) 2017; 127 Kaikita (ref_30) 2019; 119 Pignatelli (ref_26) 2010; 30 Tahrani (ref_16) 2013; 1 Gresele (ref_3) 2010; 33 Cangemi (ref_6) 2012; 61 Nusca (ref_4) 2019; 18 Nusca (ref_1) 2018; 34 Wiviott (ref_22) 2019; 380 Bailey (ref_17) 2010; 375 Neal (ref_20) 2017; 377 Packer (ref_35) 2020; 383 |
| References_xml | – volume: 152 start-page: 355 year: 2020 ident: ref_29 article-title: A novel role of MMP2 in regulating platelet NOX2 activation publication-title: Free Radic. Biol. Med. doi: 10.1016/j.freeradbiomed.2020.03.033 contributor: fullname: Nocella – volume: 20 start-page: 74 year: 2021 ident: ref_37 article-title: Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: A randomized active-controlled trial publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-021-01264-z contributor: fullname: Sposito – volume: 15 start-page: 372 year: 2013 ident: ref_19 article-title: Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise publication-title: Diabetes Obes. Metab. doi: 10.1111/dom.12054 contributor: fullname: Stenlof – volume: 127 start-page: 2133 year: 2017 ident: ref_24 article-title: Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes publication-title: J. Clin. Investig. doi: 10.1172/JCI92450 contributor: fullname: Kraakman – volume: 24 start-page: 1988 year: 2004 ident: ref_33 article-title: Reactive oxygen species: Players in the platelet game publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/01.ATV.0000145574.90840.7d contributor: fullname: Krotz – volume: 373 start-page: 1720 year: 2015 ident: ref_2 article-title: Excess Mortality among Persons with Type 2 Diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1504347 contributor: fullname: Tancredi – volume: 3 start-page: e000920 year: 2014 ident: ref_7 article-title: Different degrees of NADPH oxidase 2 regulation and in vivo platelet activation: Lesson from chronic granulomatous disease publication-title: J. Am. Heart Assoc. doi: 10.1161/JAHA.114.000920 contributor: fullname: Carnevale – volume: 381 start-page: 1995 year: 2019 ident: ref_34 article-title: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1911303 contributor: fullname: McMurray – volume: 377 start-page: 644 year: 2017 ident: ref_20 article-title: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1611925 contributor: fullname: Neal – volume: 18 start-page: 147 year: 2019 ident: ref_4 article-title: Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-019-0952-8 contributor: fullname: Nusca – volume: 61 start-page: 1626 year: 2012 ident: ref_6 article-title: Platelet isoprostane overproduction in diabetic patients treated with aspirin publication-title: Diabetes doi: 10.2337/db11-1243 contributor: fullname: Cangemi – volume: 104 start-page: 297 year: 2014 ident: ref_15 article-title: SGLT2 inhibitors in the treatment of type 2 diabetes publication-title: Diabetes Res. Clin. Pract. doi: 10.1016/j.diabres.2014.02.014 contributor: fullname: Hasan – volume: 64 start-page: 1834 year: 2021 ident: ref_31 article-title: Dapagliflozin reduces thrombin generation and platelet activation: Implications for cardiovascular risk reduction in type 2 diabetes mellitus publication-title: Diabetologia doi: 10.1007/s00125-021-05498-0 contributor: fullname: Kohlmorgen – volume: 30 start-page: 1407 year: 2010 ident: ref_14 article-title: Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.110.206425 contributor: fullname: Oeseburg – volume: 16 start-page: 102382 year: 2022 ident: ref_11 article-title: Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial publication-title: Diabetes Metab. Syndr. doi: 10.1016/j.dsx.2021.102382 contributor: fullname: Lee – volume: 182 start-page: 114276 year: 2020 ident: ref_23 article-title: The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2020.114276 contributor: fullname: Lescano – volume: 380 start-page: 347 year: 2019 ident: ref_22 article-title: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1812389 contributor: fullname: Wiviott – volume: 194 start-page: 927 year: 1962 ident: ref_27 article-title: Aggregation of blood platelets by adenosine diphosphate and its reversal publication-title: Nature doi: 10.1038/194927b0 contributor: fullname: Born – volume: 36 start-page: 2346 year: 2013 ident: ref_13 article-title: Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes publication-title: Diabetes Care doi: 10.2337/dc12-2469 contributor: fullname: Ceriello – volume: 84 start-page: 1566 year: 2018 ident: ref_28 article-title: Oleuropein, a component of extra virgin olive oil, lowers postprandial glycaemia in healthy subjects publication-title: Br. J. Clin. Pharmacol. doi: 10.1111/bcp.13589 contributor: fullname: Carnevale – volume: 383 start-page: 1413 year: 2020 ident: ref_35 article-title: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2022190 contributor: fullname: Packer – volume: 66 start-page: 385 year: 2017 ident: ref_5 article-title: Diabetes Mellitus, a prothrombotic disease publication-title: Ann. Cardiol. Angeiol. doi: 10.1016/j.ancard.2017.10.011 contributor: fullname: Picard – volume: 24 start-page: 202 year: 2014 ident: ref_8 article-title: Physiological and pathological functions of NADPH oxidases during myocardial ischemia-reperfusion publication-title: Trends Cardiovasc. Med. doi: 10.1016/j.tcm.2014.03.003 contributor: fullname: Matsushima – volume: 119 start-page: 1554 year: 2019 ident: ref_30 article-title: Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease publication-title: Thromb. Haemost. doi: 10.1055/s-0039-1693411 contributor: fullname: Kaikita – volume: 33 start-page: 1262 year: 2010 ident: ref_3 article-title: Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent publication-title: Diabetes Care doi: 10.2337/dc09-2013 contributor: fullname: Gresele – volume: 1 start-page: 208 year: 2013 ident: ref_18 article-title: Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(13)70084-6 contributor: fullname: Roden – volume: 120 start-page: 248 year: 2012 ident: ref_38 article-title: Platelet mitochondrial dysfunction is evident in type 2 diabetes in association with modifications of mitochondrial anti-oxidant stress proteins publication-title: Exp. Clin. Endocrinol. Diabetes doi: 10.1055/s-0031-1285833 contributor: fullname: Avila – volume: 4 start-page: 411 year: 2011 ident: ref_9 article-title: Optimizing platelet inhibition in clopidogrel poor metabolizers: Therapeutic options and practical considerations publication-title: JACC Cardiovasc. Interv. doi: 10.1016/j.jcin.2011.03.001 contributor: fullname: Angiolillo – volume: 1 start-page: 140 year: 2013 ident: ref_16 article-title: SGLT inhibitors in management of diabetes publication-title: Lancet Diabetes Endocrinol. doi: 10.1016/S2213-8587(13)70050-0 contributor: fullname: Tahrani – volume: 143 start-page: 770 year: 2021 ident: ref_10 article-title: Risk of Cardiovascular Outcomes in Patients with Type 2 Diabetes after Addition of SGLT2 Inhibitors versus Sulfonylureas to Baseline GLP-1RA Therapy publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.120.047965 contributor: fullname: Dave – volume: 375 start-page: 2223 year: 2010 ident: ref_17 article-title: Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(10)60407-2 contributor: fullname: Bailey – volume: 30 start-page: 360 year: 2010 ident: ref_26 article-title: Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia publication-title: Arterioscler. Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.109.198622 contributor: fullname: Pignatelli – volume: 34 start-page: e3047 year: 2018 ident: ref_1 article-title: Glycemic variability in the development of cardiovascular complications in diabetes publication-title: Diabetes Metab. Res. Rev. doi: 10.1002/dmrr.3047 contributor: fullname: Nusca – volume: 19 start-page: 46 year: 2020 ident: ref_32 article-title: Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: Potential relevance to prevention of cardiovascular events publication-title: Cardiovasc. Diabetol. doi: 10.1186/s12933-020-01016-5 contributor: fullname: Spigoni – volume: 2018 start-page: 1232583 year: 2018 ident: ref_36 article-title: Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis publication-title: J. Diabetes Res. doi: 10.1155/2018/1232583 contributor: fullname: Batzias – volume: 373 start-page: 2117 year: 2015 ident: ref_21 article-title: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1504720 contributor: fullname: Zinman – volume: 38 start-page: S8 year: 2015 ident: ref_25 article-title: (2) Classification and diagnosis of diabetes publication-title: Diabetes Care doi: 10.2337/dc15-S005 – volume: 65 start-page: 1714 year: 2016 ident: ref_12 article-title: Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis publication-title: Diabetes doi: 10.2337/db15-1141 contributor: fullname: Reheman |
| SSID | ssj0000913809 |
| Score | 2.3318334 |
| Snippet | Sodium−glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2... Sodium–glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2... Sodium-glucose co-transporter-2 inhibitors or gliflozins, the newest anti-hyperglycemic class, induce cardioprotective benefits in patients with type 2... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1878 |
| SubjectTerms | Blood clots Blood platelets Collagen CYBB protein Diabetes Diabetes mellitus (non-insulin dependent) Down-regulation gliflozins Glucose Glucose metabolism Glucose transporter Heart failure Hydrogen peroxide Immunoassay Ligands Metformin Mortality Observations Oxidants Oxidative stress Patients platelet activation Platelets Thrombosis type 2 diabetes Values |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT3BA_BMoyEhIwMFq1rGduLelYltQaSt2K-0tsh1HG6lN0HZXam99Bx6BN-NJmHGySyIOXLjGjhJ7xjPfyDPfEPJWj4yLXZExk1rLRJEkzMrYM-GTAMBN6rF2-OuJOjoXX-Zy3mv1hTlhLT1wu3F7qSqEG4kyLi0XymkteaGkFtbJTGe-ZQKNeS-YCjZYj5Is1i1LYwJx_Z7B5MFrONnYhS4beKFA1v-3Se75pGG-ZM8BTR6Q-x1ypOP2jx-SO75-RO71-AQfk58gdDptimp9-ev2x2GbjU4PGvaHwnzJOH0_PTye8Q_0c72obIXtdug3ZHD19OwCoCdIko7dpu0ZNXVBZ4tlc2nXV3SyqXWk9oYeY4c1-DA9OZ1zFtLqfEFPr6sisInTaahD2adjelZdNCuKOYs3T8j55NPs4Ih1XRiYAzS1YhAfSQESVbD1VhY-9op7o0uF2Ai22YOHS21sYNAIJX1qwS865ROjIEK1ZfKU7NRN7Z8TmilRgjtUDmNh7YUxAG7KkS7KzBqwLhF5t5FK_r0l28ghSEH55UP5ReQjCm07C0mywwNQnbxTnfxfqgOfQ5HneJRBrs50FQnws0iKlY9TIQDhgJGKyO5gJhxBNxzeKE3emYCrnKewVMxY4xF5sx3GNzGtrfbNOszReK8sYc6zVse2SwJkoZEsJyLpQPsGax6O1NUiEIRrqQF0iBf_Y5NekrscKz7wIo7vkp3Vcu1fAQ5b2dfhyP0Gfr0xyg priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLage4EHxJ3AQEZCAh6spY7jxLygblo30OiqtZP6FvkWGmlLRi_S9sZ_4Cfwz_glnJOmXSMkXmNHdvL5XGyf8x1C3qmutqF1KdOJMUy4KGImDj0TPqodcJ14zB3-NpDH5-LrJJ40B27zJqxyrRNrRe0qi2fkezwBRYoBQPzz1Q-GVaPwdrUpoXGX7PBulKYdsrN_OBiebU5ZkPUyDdWKrTGC_f2exiDCa5BwrEaXtqxRTdr_r2resk3tuMktQ9R_SB40HiTtrSB_RO748jG5v8Ur-IT8BvDpqHLF8vLPz19Hq6h0elCxWyrzGeP0w-joZMw_0i_ltDAFlt2hZ8jk6unwAlxQQJT27Lr8GdWlo-PprLo0yzntr3MeqbmhJ1hpDQamg9MJZ3V4nXf09LpwNas4HdX5KJ9ojw6Li2pBMXbx5ik57x-OD45ZU42BWfCqFgz2SbEAZKVSsYmdD73kXqtcoo8Ev9mDpUtMqKFRCxn7xIB9tNJHWsJO1eTRM9Ipq9K_IDSVIgc0pcU9sfJCa3By8q5yeWo0aJmAvF-jkl2tSDcy2Kwgflkbv4DsI2ibXkiWXT-oZt-zRvayRDphuyIPc8NhUJg_dzJWwtg4VakXMBxCnqFIA65WN5kJMFkkx8p6iRDg6YCyCshuqyeIom03rxdN1qiCeXa7cAPydtOMb2J4W-mrZd1H4f1yDH2er9bY5pPAw1BImhOQpLX6Wt_cbimLaU0UrmIFzod4-f9pvSL3OOZ04FUb3yWdxWzpX4OntTBvGnH6CwoSKxI priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELZgucAB8b-BBRkJCTgEUsdxYiSEyorugvZPtJV6i2zHoZG6CWRbqb3xDjwCb8aTMOMm3UbskWvsyLFnxvONMvMNIS9kT5nAZImvYq19noWhr6PA-tyGDoCr2GLt8PGJOBzzL5Nocpn_1BzgxZWhHfaTGtezN8sfqw9g8O8x4oSQ_a3CvMAlGC02mEuukxsMvCKmdx03UN_dyrIXJoFc8zZe8VrHLzn6_n8v6S0v1c2g3HJJgzvkdoMlaX8t_Lvkmi3vkVtbDIP3yW9QAzqssmJx_ufnr4N1fjrdr_xLUvPaZ_TV8OBoxF7Tz-W00AU24KFfkdPV0rMZgFGQLe2bthEaVWVGR9O6OteLCzpoqx-pXtEj7LkGC9OT0wnzXaKdzejpssgcvzgdusqUd7RPz4pZNaeYxbh6QMaDT6P9Q7_py-AbwFdzHyKmiIOMhZSRjjIbWMGskrlAtATHbMHnxTpQMKi4iGyswVMaYUMlIGbVefiQ7JRVaXcJTQTPwUEKg9GxtFwpgDt5T2Z5ohXcNx552Uol_b6m30ghbEH5pV35eeQjCm0zC2mz3YOq_pY2VpjGIuOmx_Mg1wwWhe9nmYgk1yZKZGI5LIciT1HdQK5GNTUK8LFIk5X2Y84Zapf0yF5nJhil6Q63SpO2Op2yGLaKOWzMI883w_gmJrqVtlq4ORL_NEcw59FaxzZbAqwhkT7HI3FH-zp77o6UxdRRhstIAgzhj__HIT0hNxnWgOCvObZHdub1wj4FZDbXz5zJ_QXyjDod priority: 102 providerName: Scholars Portal |
| Title | The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36290601 https://www.proquest.com/docview/2728420012 https://search.proquest.com/docview/2729525052 https://pubmed.ncbi.nlm.nih.gov/PMC9598474 https://doaj.org/article/76d4c14f0fb246c9952d6594bc5898e4 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Pb9MwFLe2cYED4j-FURkJCThkTRPbibl11bqB1q5aO2m3yHYcGqlNpq6VthvfgY_AN-OT8J6blEbcuPRQO7Ld5_ev-b3fI-SD7CrjmzT2VKS1x9Iw9DT3rcds6AJwFVmsHR6OxNkV-3bNr_cIr2thHGjf6PyomC-OinzmsJU3C9OpcWKd8bAvuQSjyjr7ZB_c706K7syv7IaxLzcEjSGk9B2FuME7UGpsQBc3HJDj6f_XGu-4oyZUcsf3DJ6Qx1XQSHubzT0le7Z4Rh7tUAk-J79A3nRSpvl68fvHz9MNEJ32S-8ve_nSC-inyen5NPhMvxazXOfYaYdeInmrpeM5RJ0gRNozdcczqoqUTmfLcqHXt3RQlzlSfU_PsbkaLExHF9eB5xB1NqUXd3nqiMTpxJWgfKE9Os7n5YoiXPH-BbkanEz7Z17VgMEzEEitPEiNOANhCim55qn1rQiskpnAsAh-ZgvOLdK-gkHFBLeRBpdohA2VgORUZ-FLclCUhX1NaCxYBp5QGEyDpWVKQVyTdWWaxVqBYWmRj7VUkpsNz0YC-QnKL2nKr0WOUWjbWciP7b4ol9-T6pYkkUiZ6bLMz3QAi8L-g1RwybThsYwtg-VQ5AlqMcjVqKoYATaLfFhJL2IMghuwTy1y2JgJ2meaw_WlSSrtv02CCI6KYLWgRd5vh_FJRLQVtly7ORJfKXOY82pzx7ZHgqBCIk9Oi0SN29c4c3MEVMVxg1eq8ea_n3xLHgZY4YEv3oJDcrBaru07iLtWuk0eHJ-Mxpdt978FfA5Z3Ha69wdttDSR |
| link.rule.ids | 230,314,727,780,784,864,885,2102,2221,21388,24318,27924,27925,33744,33745,43805,53791,53793,74302 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLagewAeENdRGGAkJODBWpo4TszL1E3rOui6au2kvkW-hUbaktGLtL3xH_gJ_LP9Es5J064REq-xIzv5fC62z_kOIR9lSxnP2JipSGvGbRAwHXqOcReUDriKHOYOn_RF95x_G4fj6sBtVoVVrnRiqahtYfCMfNePQJFiAJC_d_WTYdUovF2tSmjcJ1vInB42yNb-YX9wtj5lQdbL2JNLtsYA9ve7CoMIr0HCsRpdXLNGJWn_v6p5wzbV4yY3DFHnCXlceZC0vYT8Kbnn8mfk0Qav4HPyB8Cnw8Jmi8vbX7-PllHp9KBgd1TmU-bTz8Oj3sj_Qo_zSaYzLLtDz5DJ1dHBBbiggChtm1X5M6pyS0eTaXGpFzPaWeU8Un1De1hpDQam_dOxz8rwOmfp6XVmS1ZxOizzUb7SNh1kF8WcYuzizQty3jkcHXRZVY2BGfCq5gz2SSEHZIWUoQ6t85zwnZKpQB8JfrMDSxdpT0Gj4iJ0kQb7aIQLlICdqk6Dl6SRF7l7RWgseApoCoN7Yum4UuDkpC1p01gr0DJN8mmFSnK1JN1IYLOC-CV1_JpkH0Fb90Ky7PJBMf2RVLKXRMJy0-Kpl2ofBoX5-1aEkmsTxjJ2HIZDyBMUacDVqCozASaL5FhJO-IcPB1QVk2yU-sJomjqzatFk1SqYJbcLdwm-bBuxjcxvC13xaLsI_F-OYQ-28s1tv4k8DAkkuY0SVRbfbVvrrfk2aQkCpehBOeDv_7_tN6TB93RSS_pHfe_vyEPfczvwGs3f4c05tOFewte11y_q0TrLyd2Lfo |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dbtMwFLagkxBcIH5HxwAjIQEXVlPHcWJuUDfWbVC6au2k3kW246yRtmT0R9rueAcegTfjSTgnTbtGSNzWruzk_Dr-zncIeafa2no2iZgOjWEi8X1mAs8x4fwyAdehw9rh7315dCa-joNxhX-aVbDKlU8sHXVSWPxG3uIhOFIEAPFWWsEiBl-6n69-MOwghTetVTuNu2QLoqLHG2Rr76A_OF1_cUEGzMhTS-ZGH876LY2AwmuwduxMF9UiU0ng_6-b3ohTdQzlRlDqPiIPq2ySdpbif0zuuPwJebDBMfiU_AZFoMMiyRaXf37-Olwi1Ol-wW5pzaeM0w_Dw96If6TH-SQzGbbgoafI6uro4ALSUZAu7dhVKzSq84SOJtPi0ixmtLuqf6Tmhvaw6xosTPsnY85KqJ1L6Ml1lpQM43RY1qZ8oh06yC6KOUUc480zctY9GO0fsaozA7OQYc0ZnJkCAVKWSgUmSJznJHdapRLzJXjNDqJeaDwNg1rIwIUGYqWVztcSTq0m9Z-TRl7k7gWhkRQpSFZaPB8rJ7SGhCdtqySNjAaP0yTvV1KJr5YEHDEcXFB-cV1-TbKHQlvPQuLs8odieh5XdhiHMhG2LVIvNRwWhf3zRAZKGBtEKnIClkORx2jeIFerqyoF2CwSZcWdUAjIesBxNclubSaYpa0Pr5QmrtzCLL5V4iZ5ux7GfyLULXfFopyj8K45gDnbSx1bPxJkGwoJdJokrGlf7ZnrI3k2KUnDVaAgERE7_9_WG3IPrCruHfe_vST3OZZ64A0c3yWN-XThXkECNjevK8v6CzJeMic |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Sodium%E2%80%93Glucose+Co-Transporter-2+%28SGLT2%29+Inhibitors+Reduce+Platelet+Activation+and+Thrombus+Formation+by+Lowering+NOX2-Related+Oxidative+Stress%3A+A+Pilot+Study&rft.jtitle=Antioxidants&rft.au=Pasquale+Pignatelli&rft.au=Francesco+Baratta&rft.au=Raffaella+Buzzetti&rft.au=Alessandra+D%E2%80%99Amico&rft.date=2022-09-22&rft.pub=MDPI+AG&rft.eissn=2076-3921&rft.volume=11&rft.issue=10&rft.spage=1878&rft_id=info:doi/10.3390%2Fantiox11101878&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_76d4c14f0fb246c9952d6594bc5898e4 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-3921&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-3921&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-3921&client=summon |